ARID1A Knockout cell line (MFE-280)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

ARID1A (AT-rich interaction domain 1A) encodes a subunit of the SWI/SNF family of ATP-dependent chromatin remodeling complexes. ARID1A contributes to regulation of gene transcription by altering chromatin structure and accessibility and may help confer target specificity to the remodeling complex through DNA and protein interactions. It therefore plays an important role in chromatin-mediated control of gene expression.

MFE-280 is a human endometrial carcinoma cell line established from a recurrent, poorly differentiated endometrial tumor from an elderly patient. The cells were derived from tumor tissue and exhibit a complex heterogeneous karyotype. MFE-280 cells express cytokeratins, vimentin, and placental protein 14 (PP14), and have been reported to form tumors in immunodeficient mice. This cell line is used as a model for studying endometrial cancer biology and tumor-related mechanisms.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.